# Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia

> **NCT02089828** · NA · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Thromboangiitis Obliterans
- Arteritis
- Peripheral Arterial Disease

## Interventions

- **OTHER:** autologous purified CD34+ cells
- **OTHER:** autologous peripheral blood mononuclear cells

## Key facts

- **NCT ID:** NCT02089828
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089828, "Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02089828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*